To evaluate clinical outcomes, recovery trajectory, and operational advantages of consecutive-day versus alternate-day plasmapheresis schedules in patients with Guillain–Barré syndrome (GBS) managed in a high-volume public neurology ward.

This quasi-experimental study enrolled 80 adults meeting Brighton Criteria levels 1–3. Participants were allocated non-randomly into two equal groups receiving either consecutive-day or alternate-day plasmapheresis, five sessions each. Primary outcomes included improvement on the Hughes Disability Scale (HDS) at four weeks and length of hospitalization. Secondary outcomes included time to ambulation, ventilator requirement, complications, and estimated system-level cost reduction. Statistical analysis used chi-square and t-tests with significance at p

Neurological improvement at four weeks did not differ significantly between the daily and alternate-day groups (72.5% vs. 75%; p=0.78). However, consecutive-day therapy significantly reduced length of hospital stay (9.2±2.1 vs. 14.8±3.4 days; p

Daily plasmapheresis offers clinical outcomes equivalent to alternate-day therapy while markedly decreasing hospital stay and resource consumption. In overburdened public-sector hospitals, a consecutive-day protocol provides a more efficient and practical treatment strategy without compromising patient safety.